Novel oncolytic adenovirus-based PEPvIII vaccine displays a super antitumor effect in glioma models.

ABSTRACT:

Background

Currently, an epidermal growth factor receptor variant III (EGFRvIII)-specific peptide (PEPvIII) vaccine has not achieved satisfactory outcomes in several clinical trials for glioblastoma. This is probably due to the poor immunogenicity of the PEPvIII peptide vaccine and the harshly immunosuppressive tumor microenvironment. Hence, identifying strategies to enhance tumor-specific T cell immune responses and reverse immune suppression is crucial for achieving the maximum beneficial therapeutic effect.

Methods

To enhance the immunogenicity of the PEPvIII vaccine, we have developed a novel oncolytic adenovirus-based vaccine by genetically incorporating the PEPvIII peptide into the adenovirus hexon protein, naming this construct Ad5-D24-PEPvIII. However, the upregulati

SUBMITTER: Chen Y 

PROVIDER: S-EPMC12481307 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature